Phase 1 Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with AML (a type of blood cancer), B-ALL (another type of blood cancer), or MDS (a bone marrow disorder), confirmed through laboratory testing of tissue samples.
- People whose condition has not responded to all available standard treatments, or where standard treatments have been determined to not be suitable for them.
- People whose bone marrow or blood tests show at least 5% abnormal cells (blasts), which allows the trial team to measure whether the treatment is working.
- People whose cancer cells have tested positive for a specific protein called CD123, confirmed through local laboratory testing.
- People whose general physical health and ability to carry out daily activities falls within a certain range on a standard medical scale (scored 0 to 2 out of 5, where 0 means fully active and 2 means up and about more than half of waking hours) (confirm with trial site).
Who may not be able to join:
- People whose cancer has spread to the brain or the lining around the brain and spinal cord.
- People with significant heart conditions, including heart failure above a certain level of severity, unstable chest pain (including chest pain that occurs at rest), newly diagnosed chest pain within the last 6 months, or a heart attack within the 6 months before starting the trial.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Vincerx Study Director, Vincerx Pharma, Inc.
Phone: 16508006676
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of DLT (Dose limit toxicity) of VIP943
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.